Market Highlights
The Global Diabetic Retinopathy Market Is Expected To Grow At A CAGR Of 5.2% During The Forecast Period.
Diabetic retinopathy is an eye disease among the diabetic patients. It is of two types, namely, non-proliferative diabetic retinopathy and proliferative advanced diabetic retinopathy. Non-proliferative diabetic retinopathy is the early stage of the disease in which the blood vessels in the retina are weakened. Proliferative diabetic retinopathy is the advanced type of the disease in which the retina is deprived of oxygen due to circulation problems. Diabetic retinopathy can be diagnosed using tests such as fluorescein angiography and optical coherence tomography. The treatment involves the use of intraocular steroid injection, laser treatment, anti-VEGF therapy, vitrectomy, and others.
The market for diabetic retinopathy exhibits a potential growth with an increasing prevalence of diabetes and increasing awareness about diabetes management. Additionally, the huge demand for diagnostic tests for diabetic retinopathy also accelerates the growth of the market.
Some of the key players in the global market are Novartis AG (Germany), Bayer (Germany), Regeneron Pharmaceuticals Inc. (U.S.), ThromboGenics (U.S.), Actavis Plc (U.K.), Sirnaomics(U.S.), Genentech (U.S.), Alimera Sciences (U.S.), Glycadia Pharmaceuticals (U.S.), Ampio Pharmaceuticals (U.S.), Kowa Group (Japan), BCN Peptides (Spain), and others.
Get Exclusive FREE Sample Copy of Diabetic Retinopathy Market spread across 93 Premium Pages, Top 10 Companies and Supported with 78 Tables and 40 Figures is Now Available @ https://www.marketresearchfuture.com/sample_request/5792